China Pharma Holdings, Inc. (CPHI)
| Market Cap | 32.83M +466.0% |
| Revenue (ttm) | 3.91M -11.0% |
| Net Income | -4.47M |
| EPS | -0.23 |
| Shares Out | 43.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 103,395 |
| Open | 0.8200 |
| Previous Close | 0.7790 |
| Day's Range | 0.7577 - 0.8200 |
| 52-Week Range | 0.3818 - 19.1900 |
| Beta | 1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About CPHI
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, cor... [Read more]
Full Company ProfileFinancial Performance
In 2025, China Pharma Holdings's revenue was $4.14 million, a decrease of -8.49% compared to the previous year's $4.53 million. Losses were -$3.19 million, -32.70% less than in 2024.
Financial StatementsNews
China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering
HAIKOU, China, July 23, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced the closi...
China Pharma trading halted, volatility trading pause
09:30 EDT China Pharma (CPHI) trading halted, volatility trading pause
China Pharma prices 2.5M shares at $2.00 in registered direct offering
China Pharma (CPHI) Holdings announced that the pricing of its registered direct offering of 2.5M shares of its common stock at a purchase price of $2 per share. The gross…
China Pharma Announces Pricing of $5 Million Registered Direct Offering
HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today a...
China Pharma contacted by NYSE American regarding unusual market activity
China Pharma (CPHI) Holdings announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, the NYSE American has contacted the Company…
China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today a...
China Pharma says not aware of any information regarding unusual market activity
China Pharma (CPHI) Holdings announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American…
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today a...
China Pharma announces 1-for-10 reverse stock split
China Pharma (CPHI) Holdings reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, with trading to begin on a split-adjusted…
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China , April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on...
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville
HAIKOU, China , Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma announces $600,000 common stock offering
China Pharma (CPHI) Holdings announced that it has filed a prospectus supplement with the U.S. SEC under which the company may offer and sell from time to time shares of…
China Pharma Announces the Entry of "At-The-Market" Equity Offering
HAIKOU, China , Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has file...
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
HAIKOU, China , Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China , Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on ...
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
HAIKOU, China , Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...
China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs
HAIKOU, China , Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its who...
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask
HAIKOU, China , Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19
HAIKOU, China , Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
HAIKOU, China , Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spec...
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China , Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Dece...
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency
HAIKOU, China , Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Defici...
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China , July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Jul...
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...